APD791
- Generic Name
- APD791
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- F42Z27575A
- Background
APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
- Indication
For the treatment and prophylaxis of arterial thrombosis.
- Associated Conditions
- -
- Associated Therapies
- -
Dose-escalation, Repeated and Single Oral Dosing Study
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 104
- Registration Number
- NCT02419820
Safety Study of APD-791 With Aspirin and/or Clopidogrel
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT02034292
A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00619931
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
Single-Dose Safety Study of APD791 in Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2008-12-30
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT00529646
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath